AMR SVG Icons location

Over 50 Years of Specialty Injectables

American Regent develops, manufactures and supplies high-quality sterile injectables for healthcare providers and their patients.

Learn more

Dedicated to Alleviating Drug Shortages

We are committed to collaborating with the FDA to prevent or mitigate drug shortages that impact the health of patients.

Learn more

Check Product Availability

Updated June 22, 2021 09:21 AM

View All

Atropine Sulfate

  • 0.4 mg/mL | 1 mL Single Dose Vial
  • Shelf Pack — 25

HydrALAZINE Hydrochloride

  • 20 mg/mL | 1 mL Single Dose Vial
  • Shelf Pack — 25

Papaverine HCL

  • 30 mg/mL | 2 mL Single Dose Vial
  • Shelf Pack — 25

Zinc Sulfate 

  • 5 mg/mL | 5 mL Pharmacy Bulk Package Vial
  • Shelf Pack — 25

News Center

Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia

Basking Ridge, N.J. and Shirley, N.Y. (May 6, 2021): Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer® (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron, have had unsatisfactory response to oral iron, or have non-dialysis dependent chronic kidney disease (CKD).1

American Regent, Inc. Announces New CEO

Shirley, NYApril 1, 2021: Paul Diolosa assumed the role of President and CEO of American Regent, Inc., a Daiichi Sankyo Group company, effective today.

American Regent, Inc. introduces Tralement® (trace elements injection 4*, USP)

Melville, NY – September 30, 2020: American Regent, Inc. announces the introduction of Tralement® (trace elements injection 4*, USP), the first and only FDA-approved multi-trace element injection.

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent database, please submit a message request to corpcommunications@americanregent.com.